ASGR1: Exploration and Challenges of a New Target for Lipid-lowering Therapy

Introduction

In modern life, people's dietary habits often tend to the intake of high - fat and high - sugar foods. The excessive consumption of such foods promotes an increase in lipid synthesis in the body, which in turn leads to hyperlipidemia and an increased risk of cardiovascular diseases. Currently, there is a wide variety of lipid - lowering drugs. Common ones include statins, cholesterol absorption inhibitors, and fibrates. However, after treatment with these drugs, some patients still fail to achieve the desired blood lipid levels and may even experience adverse reactions such as elevated transaminases, muscle pain, and fatigue. In view of this, the exploration of new targets for lipid - lowering therapy and the research and development of new lipid - lowering drugs are ongoing.

Cholesterol Metabolism and the Prevention and Treatment of Cardiovascular Diseases

Hypercholesterolemia, as an important risk factor for cardiovascular and metabolic diseases, its treatment strategies have always been a key area of medical research. Currently, the cholesterol - lowering drugs used in clinical practice mainly act on several classic targets: Statins reduce cholesterol synthesis by inhibiting HMGCR; ACLY inhibitors such as Bempedoic acid block the generation of acetyl - CoA; NPC1L1 inhibitors such as Ezetimibe inhibit intestinal cholesterol absorption. The low - density lipoprotein receptor (LDLR) system, as a key pathway for cholesterol clearance, its regulatory mechanism has also been successfully applied in clinical practice. In particular, siRNA, ASO, and antibody therapies targeting PCSK9 significantly enhance cholesterol clearance efficiency by preventing LDLR degradation. Although statins are highly effective and have good safety, there are still limitations such as the risk of myopathy, abnormal glucose metabolism, and some patients show treatment intolerance, and the residual inflammatory risk persists. These clinical needs drive the exploration of new targets.

Breakthrough in the Cholesterol - Lowering Mechanism of ASGR1

Recent research has revealed the unique role of asialoglycoprotein receptor 1 (ASGR1) in cholesterol metabolism. An important study published by the research team of Wuhan University in Nature shows that ASGR1 inhibition can exert a lipid - lowering effect through a dual mechanism: on the one hand, it promotes the expression of ABCA1 and ABCG5/G8 through the AMPK - LXRα pathway, enhancing reverse cholesterol transport and biliary excretion; on the other hand, it reduces lipid synthesis by inhibiting the mTORC1 - SREBP1 signal. This mechanism is different from traditional LXR agonists, avoiding the problem of increased lipid synthesis caused by simple activation of LXR. Experiments have confirmed that ASGR1 - neutralizing antibodies can not only exert a lipid - lowering effect alone but also produce a synergistic effect with statins or Ezetimibe, providing new ideas for combination therapy.

Potential Risks of ASGR1 - Targeted Therapy

Although ASGR1 - targeted therapy has broad prospects, its potential risks cannot be ignored. An increase in biliary cholesterol content may increase the risk of gallstone formation; although no liver damage was observed in mouse experiments, the impact of the remodeling of hepatocyte energy metabolism caused by changes in cholesterol efflux in humans still needs to be verified. In addition, ASGR1 is involved in the regulation of platelet renewal, and its inhibition may affect platelet function. As a clearance receptor for a variety of glycoproteins, ASGR1 inhibition may also disrupt the balance of glycoprotein metabolism in the body. It is particularly noteworthy that ASGR1 is the hepatic - targeting delivery receptor for GalNAc - modified drugs, and potential interactions with GalNAc - ASO drugs need to be avoided.

Future Prospects

The liver - specific expression pattern of ASGR1 makes it a therapeutic target with great development potential. Although there are many unsolved problems, the discovery of this target has opened up a new way for the treatment of hypercholesterolemia and related metabolic diseases. Future research needs to focus on solving several key problems: systematically evaluating the long - term safety of ASGR1 inhibition in large - animal models; clarifying the differences in efficacy among different populations; and exploring the optimal combination scheme with other lipid - lowering drugs. These studies will provide important evidence for the translation of ASGR1 - targeted drugs from the laboratory to the clinic, and are expected to bring breakthrough progress in blood lipid management.